摘要
目的评价愈肠宁胃-结肠分释胶囊的药效,并探讨其作用机制。方法 SD大鼠48只,按体重随机分为正常组、对照组、阳性对照组、愈肠宁胃-结肠分释胶囊低剂量组(胶囊低剂量组)、愈肠宁胃-结肠分释胶囊高剂量组(胶囊高剂量组)、愈肠宁溶液组(溶液组),每组8只。正常组、对照组均给予同体积生理盐水,阳性对照组给予柳氮磺吡啶肠溶片,其余3组分别给予不同剂量的愈肠宁胃-结肠分释胶囊和愈肠宁溶液。各组给药3d后,以三硝基苯磺酸诱导建立大鼠溃疡性结肠炎模型,各组继续给药至8d后结束实验,取大鼠结肠组织测定肠重系数,观察并评价给药后结肠组织损伤指数,同时检测结肠组织髓过氧化物酶(MPO)、TNF-α、IL-1β、超氧化物歧化酶(SOD)、丙二醛(MDA)水平。结果与正常组比较,对照组大鼠肠重系数、结肠组织损伤指数差异显著,结肠组织SOD水平显著降低,MPO、TNF-α、IL-1β、MDA水平显著升高。与对照组相比,各给药组大鼠肠重系数、结肠组织损伤指数(P<0.05,P<0.01)以及MPO、TNF-α、IL-1β、MDA水平均显著降低;胶囊高剂量组、阳性对照组大鼠结肠组织SOD水平均显著升高。与溶液组相比,阳性对照组、胶囊高剂量组大鼠肠重系数、结肠组织损伤指数均显著降低(P<0.05,P<0.01);胶囊高剂量组大鼠结肠组织SOD水平明显升高,MPO、TNF-α、IL-1β水平均显著降低(P<0.05,P<0.01),MDA水平则无明显差异。结论通过抑制炎性细胞浸润和促炎因子的异常释放,以及调节失衡的氧自由基系统等作用机制,愈肠宁胃-结肠分释胶囊表现出与同剂量愈肠宁溶液相比更明显的疗效优势,具有良好应用前景。
Objective To evaluate the pharmacodynamic action of Yuchangning capsule releasing drug respectively in stomach and colon, and explore the mechanism of action. Methods The forty-eight SD rats were randomly individed into normal group, control group, positive control group, the low dose of capsule group, the high dose of capsule group and liquor group with eight rats in each group. The rats in the normal and control groups were perfused with the same volume physiological saline, the rats in the positive control group were perfused with sulfasalazine, and the rats in the other three groups were perfused with the different doses of Yuchangning capsule releasing drug respectively in stomach and colon and Yuchangning liquor. 3 days after the perfusion, the trinitro-benzene-sulfonic acid was perfused into the rats in order to establish the rat model of ulcerative colitis, and the experiment was finished on the 8th day after continuous perfusion. The colon tissue of rats were taken to determine the coefficient of colon weight, observe and evaluate the exponent of colon injury, and detect the level of MPO, TNF-α, IL-1β, SOD and MDA in colon tissue. Results Compared with the normal group, the coefficient of colon weight and exponent of colon injury showed remarkable differences, the level of SOD in colon tissue remarkably decreased, and the level of MPO, TNF-α, IL-1β, MDA remarkably increased in the control group. Compared with the control group, the coefficient of colon weight, exponent of colon injury （P 〈 0.05, P 〈 0.01） and the level of MPO, TNF-α, IL-1β and MDA all remarkably decreased in the other groups, the level of SOD remarkably increased in the high dose of capsule group and positive control group. Compared with the liquor group, the coefficient of colon weight and exponent of colon injury both remarkably decreased （P 〈 0.05, P 〈 0.01） in the hige dose of capsule group and positive control group; At the same time, the level of SOD remarkably increased, and the level of MPO, TNF-α, IL-1β a
出处
《中国医药生物技术》
CSCD
2011年第2期111-115,共5页
Chinese Medicinal Biotechnology
基金
国家"重大新药创制"科技重大专项(2009ZX09103-307)
关键词
结肠炎
溃疡性
疾病模型
动物
中草药
迟效制剂
胶囊
Colitis, ulcerative
Disease models, animal
Drug, Chinese hebal
Delayed-action preparations
Capsules
